BIOCRYST PHARMACEUTICALS INC — Form 8-K/A
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 18/100
What the filing says
BioCryst filed an amended 8-K/A on August 4, 2026, disclosing Item 2.05 regarding costs associated with exit or disposal activities as of June 25, 2026. The filing document itself contains no substantive dollar amounts, percentages, share counts, or concrete details of what activities triggered the amendment or what costs were incurred — only structural metadata and XBRL filing tags are visible in this submission.
Why this rating
Amendment is routine disclosure correction; no material dollar figures or operational details disclosed in filing text provided; cannot assess magnitude relative to $1.9B market cap.
Extracted items
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.